Inhibition of the NLRP3 inflammasome improves lifespan in animal murine model of Hutchinson-Gilford Progeria
- PMID: 34448355
- PMCID: PMC8495449
- DOI: 10.15252/emmm.202114012
Inhibition of the NLRP3 inflammasome improves lifespan in animal murine model of Hutchinson-Gilford Progeria
Abstract
Inflammation is a hallmark of aging and accelerated aging syndromes such as Hutchinson-Gilford progeria syndrome (HGPS). In this study, we present evidence of increased expression of the components of the NLRP3 inflammasome pathway in HGPS skin fibroblasts, an outcome that was associated with morphological changes of the nuclei of the cells. Lymphoblasts from HGPS patients also showed increased basal levels of NLRP3 and caspase 1. Consistent with these results, the expression of caspase 1 and Nlrp3, but not of the other inflammasome receptors was higher in the heart and liver of Zmpste24-/- mice, which phenocopy the human disease. These data were further corroborated in LmnaG609G/G609G mice, another HGPS animal model. We also showed that pharmacological inhibition of the NLRP3 inflammasome by its selective inhibitor, MCC950, improved cellular phenotype, significantly extended the lifespan of progeroid animals, and reduced inflammasome-dependent inflammation. These findings suggest that inhibition of the NLRP3 inflammasome is a potential therapeutic approach for the treatment of HGPS.
Keywords: NLRP3 inflammasome; aging; progeria.
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures

Western blot analysis with representative blot including lamin A/C, NLRP3, caspase 1, and actin levels in skin fibroblasts from patients with HGPS, n = 2 controls and 2 patients. Positive control correspond to THP1 cells stimulated with LPS+ATP.
Immunofluorescence (IF) visualization of NLRP3 (green) and nuclei (blue) in skin fibroblasts from a representative patient and control. Scale bar: 30 µm.
Protein expression of NLRP3 and caspase 1 in lymphoblasts from control and one patient after stimulation with uric acid and cholesterol crystal.
IL‐1β and IL‐18 medium release from lymphoblasts which were assessed after a 24‐h incubation with uric acid and cholesterol. ***P < 0.001, **P < 0.005, * treatment vs no treatment; aaa P < 0.001; aa P < 0.01 control cells vs patient cells.
Western blot analysis with representative blot including NLRP3, caspase 1, IL‐1β and actin levels in heart and liver tissues from wild‐type and Zmpste24−/− mice.
NLRP3 and caspase 1 transcript expression levels were determined in heart and liver tissues by real‐time quantitative RT–PCR. n = 5 for Zmpste24+/+ and n = 5 for Zmpste24−/− groups respectively. ***P < 0.001, **P < 0.005, wild‐type vs Zmpste24−/− mice. Data are showed means ± SD, n = 4 mice per group.



- A
Cell growth (lower subpanel left patient 1 and right patient 2) and morphological aspect (upper subpanel) with MCC950 determined in healthy and representative HGPS fibroblasts. **P < 0.01, *P < 0.05 patient cells no treatment vs treatment. Results are presented as the mean ± SD of three independent experiments.
- B
Western blot analysis with representative blots including lamin A/C, NLRP3, IL‐1β, and actin levels in skin fibroblasts from control and HGPS patient after 48 h of vehicle and MCC950 treatment.
- C–E
Representative fluorescence images of HGPS and control fibroblasts to evaluate the effect of the MCC950 in the nuclear morphology (D) and NLRP3 expression (E). Scale bar: 30 µm. Results are presented as the mean ± SD of three independent experiments. ***P < 0.01 patient vs control cells, aaa P < 0.01 patient cells no treatment vs treatment. One‐way ANOVA test was used for statistical analysis.
- F
Kaplan–Meier graph showing a significant increase in the maximum lifespan in WT mice compared with Zmpste24−/− mice. N = 7 per group.
- G
Body weights evolution of the groups over time. Data are showed means ± SD, n = 6 mice per group.
- H
Analysis of serum concentrations of IL‐1β measured by ELISA. N = 6 per group. Data are shown as means ± SD. ***P < 0.001, wild‐type vs Zmpste24−/− mice; aaa P < 0.001; vehicle vs MCC950.
Similar articles
-
Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.J Proteomics. 2013 Oct 8;91:466-77. doi: 10.1016/j.jprot.2013.08.008. Epub 2013 Aug 20. J Proteomics. 2013. PMID: 23969228
-
The NLRP3 inhibitor Dapansutrile improves the therapeutic action of lonafarnib on progeroid mice.Aging Cell. 2024 Sep;23(9):e14272. doi: 10.1111/acel.14272. Epub 2024 Aug 27. Aging Cell. 2024. PMID: 39192596 Free PMC article.
-
Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.Circulation. 2018 Jul 17;138(3):266-282. doi: 10.1161/CIRCULATIONAHA.117.030856. Epub 2018 Feb 28. Circulation. 2018. PMID: 29490993 Free PMC article.
-
Hutchinson-Gilford progeria syndrome: clinical findings in three patients carrying the G608G mutation in LMNA and review of the literature.Br J Dermatol. 2007 Jun;156(6):1308-14. doi: 10.1111/j.1365-2133.2007.07897.x. Epub 2007 Apr 25. Br J Dermatol. 2007. PMID: 17459035 Review.
-
Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.Cells. 2021 May 11;10(5):1157. doi: 10.3390/cells10051157. Cells. 2021. PMID: 34064612 Free PMC article. Review.
Cited by
-
Cell and Cell-Free Therapies to Counteract Human Premature and Physiological Aging: MSCs Come to Light.J Pers Med. 2021 Oct 18;11(10):1043. doi: 10.3390/jpm11101043. J Pers Med. 2021. PMID: 34683184 Free PMC article. Review.
-
Inflammation and aging: signaling pathways and intervention therapies.Signal Transduct Target Ther. 2023 Jun 8;8(1):239. doi: 10.1038/s41392-023-01502-8. Signal Transduct Target Ther. 2023. PMID: 37291105 Free PMC article. Review.
-
DNA damage and repair in age-related inflammation.Nat Rev Immunol. 2023 Feb;23(2):75-89. doi: 10.1038/s41577-022-00751-y. Epub 2022 Jul 13. Nat Rev Immunol. 2023. PMID: 35831609 Free PMC article. Review.
-
The Impact of Inflammatory Stimuli on Xylosyltransferase-I Regulation in Primary Human Dermal Fibroblasts.Biomedicines. 2022 Jun 19;10(6):1451. doi: 10.3390/biomedicines10061451. Biomedicines. 2022. PMID: 35740472 Free PMC article.
-
Progerin, an Aberrant Spliced Form of Lamin A, Is a Potential Therapeutic Target for HGPS.Cells. 2023 Sep 18;12(18):2299. doi: 10.3390/cells12182299. Cells. 2023. PMID: 37759521 Free PMC article. Review.
References
-
- Afonina IS, Zhong Z, Karin M, Beyaert R (2017) Limiting inflammation‐the negative regulation of NF‐κB and the NLRP3 inflammasome. Nat Immunol 18: 861–869 - PubMed
-
- Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, Chitty JL, Fraser JA, Jennings MP, Robertson AAB et al (2019) MCC950 directly targets the NLRP3 ATP‐hydrolysis motif for inflammasome inhibition. Nat Chem Biol 15: 556–559 - PubMed
-
- Cordero MD, Williams MR, Ryffel B (2018) AMP‐activated protein kinase regulation of the NLRP3 inflammasome during aging. Trends Endocrinol Metab 29: 8–17 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous